Latest news

• Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

  This increase can be attributed to Lily’s key growth products, including Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz.

• Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

  Although median overall survival (OS) was not reached in both groups, OS showed an improvement favouring the Tyvyt combination. ... Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications.

• China updates drug reimbursement list, agrees price cuts

  Also included on the updated list is the PD-1 inhibitor Tyvyt (sintilimab) – jointly developed by Innovent Biologics and Eli Lilly – for the treatment of relapsed/refractory Hodgkin’s lymphoma. ... If approved, it could directly rival

• Innovent gears up for PD-1 inhibitor launch in China

  Chinese biotech Innovent is in the final stages of preparing to launch its cancer immunotherapy Tyvyt in its home market. ... The approval of Tyvyt…enables Innovent's delivery on its social responsibility to offer innovative drugs affordable to